Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2022 | Enhancing immunotherapies with high endothelial venules

Lucas Blanchard • 21 Nov 2022
SITC 2022
General Antibodies Checkpoint Inhibitors

High endothelial venules (HEVs) have been found to play a role in the movement of stem-like CD8+ T cells from the lymph node to tumors in patients receiving immunotherapy. Lucas Blanchard, MS, CNRS-IPBS, Toulouse, France, describes clinical implications of these findings. Neoadjuvant immunotherapy may benefit patients more by optimizing CD8+ T cell response and increasing the presence of HEVs will additionally enhance the recruitment of T cells. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Lucas Blanchard

1:07
How can high endothelial venules move CD8+ T cells into the tumor during IO?
Lucas Blanchard • 21 Nov 2022

Related Videos

0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
3:10
PALOMA: subcutaneous amivantamab in advanced solid tumors
Natasha Leighl • 17 Apr 2024
The content of VJOncology is intended for healthcare professionals